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ABSTRACT
LGR5 is a marker of normal and cancer stem cells in various tissues where 
it functions as a receptor for R-spondins and increases canonical Wnt signalling 
amplitude. Here we report that LGR5 is also highly expressed in a subset of high 
grade neuroblastomas. Neuroblastoma is a clinically heterogenous paediatric 
cancer comprising a high proportion of poor prognosis cases (~40%) which are 
frequently lethal. Unlike many cancers, Wnt pathway mutations are not apparent in 
neuroblastoma, although previous microarray analyses have implicated deregulated 
Wnt signalling in high-risk neuroblastoma. We demonstrate that LGR5 facilitates high 
Wnt signalling in neuroblastoma cell lines treated with Wnt3a and R-spondins, with 
SK-N-BE(2)-C, SK-N-NAS and SH-SY5Y cell-lines all displaying strong Wnt induction. 
These lines represent MYCN-amplified, NRAS and ALK mutant neuroblastoma subtypes 
respectively. Wnt3a/R-Spondin treatment also promoted nuclear translocation of 
β-catenin, increased proliferation and activation of Wnt target genes. Strikingly, 
short-interfering RNA mediated knockdown of LGR5 induces dramatic Wnt-
independent apoptosis in all three cell-lines, accompanied by greatly diminished 
phosphorylation of mitogen/extracellular signal-regulated kinases (MEK1/2) and 
extracellular signal-regulated kinases (ERK1/2), and an increase of BimEL, an 
apoptosis facilitator downstream of ERK. Akt signalling is also decreased by a Rictor 
dependent, PDK1-independent mechanism. LGR5 expression is cell cycle regulated 
and LGR5 depletion triggers G1 cell-cycle arrest, increased p27 and decreased 
phosphorylated retinoblastoma protein. Our study therefore characterises new 
cancer-associated pathways regulated by LGR5, and suggest that targeting of LGR5 
may be of therapeutic benefit for neuroblastomas with diverse etiologies, as well as 
other cancers expressing high LGR5.
INTRODUCTION
Neuroblastoma (NB) is one of the commonest 
extracranial paediatric solid tumours, arising from neural 
crest progenitor cells of the sympathetic nervous system 
which have failed to undergo regulated differentiation 
and development as a result of aberrant gene expression 
programmes instigated by critical oncoproteins [1, 2]. The 
two best studied, and genetically modelled, drivers of NB 
are the transcription factor MYCN [3] and the receptor 
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tyrosine kinase anaplastic lymphoma kinase (ALK) [4]. 
Gene amplification of the MYCN proto-oncogene occurs 
in about 50% of high-risk NBs (~20% of total NBs), and 
activating ALK point mutations occur in about 10% of NBs 
and encompass all clinical subtypes [4–6]. The oncogenic 
p.F1174L ALK mutant has been shown to potentiate 
the tumorigenic effect of MYCN in a mouse model, 
leading to higher penetrance, earlier onset and increased 
lethality [7]. This pronounced effect on tumorigenicity 
was accompanied by dramatic activation of the mitogen-
activated protein kinase (MAPK) and phosphoinositide 
3-kinase/Akt (PI3K/Akt) pathways. Both PI3K/Akt and 
MAPK signalling pathways are frequently deregulated in 
cancer, and represent targets for therapeutic intervention 
[8, 9]. Indeed elevated Akt signalling has been shown 
to be an indicator for poor prognosis NB [10] and PI3K 
inhibition can lead to decreased levels of MYCN protein 
in NB cells [11]. Activation of the mitogen/extracellular 
signal-regulated kinases (MEK1/2)/extracellular signal-
regulated kinases (ERK1/2) was also frequently observed 
in NB [10], and a low frequency of missense mutations 
of genes in the Ras-Raf-MEK/ERK pathway has been 
reported in NB [5, 6, 12]. Importantly, two very recent 
studies have demonstrated that mutations in this pathway 
are more frequent in relapsing NB [13, 14].
Another signalling pathway that is frequently 
disrupted during tumorigenesis is the canonical Wnt/β-
catenin pathway. Here signal transduction begins with 
binding of secreted Wnt ligands to Frizzled and LRP5/6 
receptors, which triggers inactivation of a cytoplasmic 
“destruction complex” controlling the cellular pool of 
the transcriptional co-activator β-catenin. As β-catenin 
increases, it can translocate to the nucleus and activate 
T-cell factor/lymphoid enhancer factor (TCF/LEF) 
transcription factors, leading to induced expression of 
key genes involved in proliferation, differentiation, 
metabolism and stemness [15, 16]. Wnt signalling 
amplitude can be increased by the R-spondin family 
of growth factors (Rspo1-4) binding to leucine-
rich repeat-containing G-protein coupled receptors 
(LGRs) such as LGR5 [17, 18]. The LGR-Rspo complex 
then recruits and promotes membrane clearance of 
the E3 ubiquitin ligase ZNRF3/RNF43, which would 
otherwise participate in turnover of the Wnt receptor 
complex at the cell-surface. Thus LGR-Rspo binding 
leads to accumulation of Frizzled and LRP6 receptors 
at the plasma membrane and enhanced Wnt signaling 
[19]. LGR5 is an established marker of the intestinal 
stem cell niche, and also marks stem cells in other tissues 
[15]. LGR5 expressing cells behave like cancer stem 
cells (CSCs) in breast [20] and colorectal cancer [21], 
glioblastoma [22], and a mouse-model of papillomavirus-
induced squamous cell carcinoma [23].
Unlike many other cancers, defects in Wnt pathway 
genes, such as activating mutations of CTNNB1, encoding 
β-catenin, have not been found in NB, and NB cell-lines do 
not exhibit Wnt signalling activity measured by TCF/LEF 
reporter plasmids. However, tumour samples from high-
risk NB patients with and without MYCN amplification 
express canonical Wnt pathway target genes at high levels, 
indicative of Wnt deregulation in NB [24]. Intriguingly, 
LGR5 mRNA was also shown to be elevated when NB 
xenografts were propagated as sphere cultures. These 
cultures also exhibited high expression of Wnt target 
genes, and displayed higher tumorigenicity in vivo [25].
In this study, we examine the expression and 
functions of LGR5 in NB. Our data suggests that LGR5 
plays a key role in not only regulating Wnt signalling, but 
also MEK/ERK signalling in neuroblastoma cells, thereby 
regulating proliferation and survival respectively.
RESULTS
Expression pattern of LGR5 in NB cell lines and 
tumour tissues
In silico analysis of NB microarray datasets 
was carried out using the R2 Genomics Analysis and 
visualization Platform (http://r2.amc.nl) in datasets 
with clinical correlates for both MYCN-unamplified 
and MYCN-amplified NBs [26, 27]. High LGR5 mRNA 
expression correlated with low probability of relapse-
free survival in both datasets (Bonferroni corrected 
p = 6.4e-05 and p = 2.8e-06, see Figure 1A). We therefore 
examined LGR5 protein levels in primary NBs using 
immunoblotting in panel of 26 NBs, and observed 
higher expression of LGR5 in stage 3 and 4 tumours 
relative to stage 1 and 2 tumours and normal fetal adrenal 
(Figure 1B). Immunohistochemical analysis showed that 
cytoplasmic LGR5 staining was observed in 9/25 poorly 
differentiated tumours (36%) and only 1/7 differentiating 
NBs (14%) (Figure 1C). Similarly 7/15 NB cell-lines 
showed high levels of LGR5 protein (Figure 1D). Cells 
with high expression did not segregate with established 
NB etiological factors such as MYCN amplification or 
ALK mutation (Supplementary Table 1). The increased 
expression of LGR5 in poorly differentiated and high 
stage primary NBs and NB cell lines suggests that 
certain subsets of NBs are competent for Wnt signalling 
dependent on Wnt and R-Spondin ligands.
Canonical Wnt signalling capacity of LGR5 
expressing NB cell lines
The effect of Wnt3a and R-spondin ligands 
on stimulation of Wnt/β-catenin signalling pathway 
was examined by the TOPFLASH reporter assay in 
SK-N-BE(2)-C and SH-SY5Y cell lines, which represent 
MYCN-amplified and ALK-mutated cells respectively 
(see Supplementary Table 1). Wnt3a treatment alone 
increased TOPFLASH activity in SK-N-BE(2)-C 
by approximately 14-fold, but addition of any of the 
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R-spondins 1–3 dramatically increased TOPFLASH 
activity to 83-fold with Rspo1, 129-fold with 
Rspo2 and 147-fold with Rspo3 (p < 5.0e-04). In the case of 
SH-SY5Y cells, no TOPFLASH induction was apparent 
with Wnt3a alone, but a 50–100 fold increase was 
apparent on addition of Rspo ligands (p < 5.0e-03). The Wnt 
activity in the Wnt3a/Rspo-treated SK-N-BE(2)-C and 
SH-SY5Y cells was comparable to the colorectal cancer 
Figure 1: Expression of LGR5 in neuroblastoma. A. Kaplan-Meier survival curves derived from 2 independent microarray 
analyses of neuroblastomas showing the association of high LGR5 mRNA expression with poor prognosis. Datasets used are from reference 
[27] (left) and [26] (right), obtained using the R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl). B. Immunoblotting 
showing elevated expression of LGR5 in primary NBs. Fetal Adrenal protein is shown as a normal control(FA). C. Immunohistochemistry 
demonstrating prominent cytoplasmic staining in poorly differentiated NBs (top) and little or no staining in differentiating NBs (bottom). 
A section of normal colon where interspersed LGR5 positive cells are located at the bottom of crypts is shown as a control. D. Immunoblotting 
showing elevated expression of LGR5 in cell-lines. The colorectal cancer cell line LOVO is shown for comparison.
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line HCT116 which has an activating point-mutation of 
β-catenin and constitutive Wnt activation (Figure 2A). 
Similar Wnt/Rspo2 responsiveness was also observed 
in the SK-N-AS cell-line (Supplementary Figure 1). To 
confirm that TOPFLASH activity was indeed reliant on 
LGR5, we first knocked down LGR5 in SK-N-BE(2)-C 
and SH-SY5Y cells, and then treated them with Wnt3a/
Rspo2 before reporter assays. As shown in Figure 2B, 
knockdown of either LGR5 or β-catenin led to greatly 
reduced TOPFLASH activity.
We next evaluated whether co-stimulation with 
Wnt3a/Rspo2 resulted in nuclear translocation of β-catenin 
using confocal microscopy. Distinct nuclear translocation 
of β-catenin was visible in SK-N-BE(2)-C, SH-SY5Y and 
SK-N-AS cell lines when stimulated with Wnt3a/Rspo2 
(Figure 2C). To evaluate the effect of Wnt3a/Rspo2 on 
cell growth, we monitored the median fluorescence 
intensity (MFI) of the proliferation marker Ki67 using 
flow cytometry, and found increases accompanying 
Wnt3a/Rspo2 treatment in all three lines tested, especially 
SK-N-AS and SK-N-BE(2)-C (Figure 2D).
In order to further confirm Wnt activation, we 
analysed induction of several established target genes 
of canonical Wnt signalling in the NB cell lines treated 
with Wnt3a/Rspo2, including AXIN2, BMP4, JAG1, 
TNFRSF19, and TWIST1 (http://web.stanford.edu/group/
nusselab/cgi-bin/wnt/). Robust induction of all these 
genes was observed (Supplementary Figure 2A). We 
also evaluated MYC and MYCN, which are also reported 
Wnt targets, but neither was markedly elevated. c-MYC 
and MYCN protein expression was also examined, and 
showed that neither c-MYC (SK-N-AS and SH-SY5Y) 
or MYCN (SK-N-BE(2)-C) was upregulated with Wnt3a/
Rspo2 treatment (Supplementary Figure 2B).
Taken together these studies establish LGR5 as a 
key mediator of proliferative canonical Wnt signalling in 
neuroblastoma cells. 
LGR5 depletion induces apoptosis of NB cells 
independent of Wnt/β-catenin signalling
During the course of our TOPFLASH experiments, 
we observed that knockdown of LGR5 for greater than 48 
hrs had a dramatic effect on cell survival. We therefore 
sought to further characterise the effects of LGR5 
depletion in our panel of NB lines. Although there is no 
constitutive Wnt signalling apparent in NB cell lines as 
assessed by the TOPFLASH reporter assay (Figure 2, 
[24]), we further assessed whether the cell-death induced 
by LGR5 depletion involved a low residual level of Wnt/
β-catenin signalling. Whereas LGR5 knockdowns in all 
three lines induced significant cell-death (p < 0.05), no 
effects were observed in β-catenin knockdowns (Figure 3). 
Transcriptionally active β-catenin is unphosphorylated 
at critical serine and threonine residues, and can be 
specifically detected with an anti-active β-catenin antibody 
[28]. Our immunoblotting demonstrates that active 
β-catenin was not detected in the nuclear fractions from 
the 3 cell lines (Figure 3B).
In both SK-N-AS and SH-SY5Y cells, knockdown 
of LGR5 with 2 independent siRNAs was accompanied by 
visible cell death (p < 0.05). Immunoblotting showed an 
increase in cleaved poly ADP ribose polymerase (PARP) 
in LGR5 knockdowns, and cell death was rescued by 
treatment with the caspase inhibitor Q-VD-OPh (QVD). 
Flow cytometry measuring membrane asymmetry 
also confirmed apoptotic cell death (Figure 4). Similar 
apoptosis accompanying LGR5 depletion was observed in 
SK-N-BE(2)-C cells (Supplementary Figure 3).
Together with our reporter assays, these experiments 
confirm that there is no basal Wnt signalling in the NB 
cell lines examined, and that the dramatic effects of 
LGR5 knockdown must be attributable to other signalling 
pathways.
LGR5 regulates MEK/ERK and Akt signalling 
pathways
As cancer cell survival can involve MEK/ERK and 
Akt signalling pathways [9, 29], we assessed whether 
LGR5 knockdown had any effects on the activated 
(phosphorylated) forms of these kinases. Both phospho-
serine MEK1/2 (S217/221) and phospho-serine ERK1/2 
(T202/Y204) were dramatically decreased in SK-N-AS 
and SK-N-BE(2)-C cell lines, with SH-SY5Y cells also 
displaying a decrease, albeit slightly less pronounced. 
Total MEK and ERK were not changed after 48 hrs 
of knockdown, but showed a slight decrease after 
72 hrs (Figure 5A). We also assessed total c-Raf and 
phospho-serine (S338) c-Raf as Raf is an intermediary 
of Ras-MEK-ERK signalling. However, no changes in 
total or phospho-c-RAF(S338) were apparent (data not 
shown). As the BH3-only protein Bim (Bcl-2 interacting 
mediator of cell death) is directly phosphorylated by 
ERK1/2, leading to its degradation and unavailability 
to pro-survival members of the Bcl-2 family [30, 31], 
we assessed the effect of LGR5 depletion on BimEL by 
immunoblotting. Knockdowns in all 3 cell-lines tested 
resulted in elevated BimEL, supporting LGR5-ERK-Bim 
signalling as a pro-survival pathway in NB (Figure 5B).
We also examined phosphorylated (S473 and 
T308) and total Akt changes. Whilst the PDK1-
mediated phosphorylation of T308 remained unchanged, 
phosphorylation of S473 was greatly diminished 
following LGR5 knockdown (Figure 5C). Consistent 
with the unaltered p-Akt(T308), phospho-PDK1 
(S241) was also unaffected. As PDK1 is downstream of 
phosphatidylinositide 3-kinase (PI3K), this data suggests 
that early LGR5 effects are not linked to the PI3K 
pathway, although at 72 hrs some decreases are apparent. 
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Early effects on Akt signalling largely affect p-Akt(S473) 
in all cell lines. This modification is known to depend 
on by the Rictor-mTOR complex [32], and consistent 
with this, decreased Rictor is apparent following LGR5 
knockdown in all cell-lines, whereas mTOR is unaltered 
except in SK-N-BE(2)-C cells.
The SH-SY5Y cell line is known to have an 
activating mutation of the ALK gene [4], and mutant ALK 
activates MEK/ERK signalling [7]. We therefore examined 
whether LGR5 knockdown might lead to a reduction 
in ALK and phospho-ALK levels. However, in both 
SH-SY5Y and SK-N-BE(2)-C lines,  phospho-ALK was 
Figure 2: Wnt3a and R-spondin responsiveness of neuroblastoma cell lines. A. TOPFLASH reporter assay for SK-N-BE(2)-C 
and SH-SY5Y showing increased luciferase activity upon co-stimulation with Wnt3a and Rspos 1–3 ( p < 5.0e-04 and p < 5.0e-03 respectively). 
B. TOPFLASH reporter assay combined with control siRNA, LGR5 or β-catenin targeting siRNAs, demonstrating requirement for LGR5 
for reporter activity ( p < 0.05). Reporter assays were conducted at least twice in triplicate. PBS: Phosphate-buffered saline, WR2: Wnt3a/
Rspo2 treatment. C. Confocal microscopy of β-catenin nuclear translocation in SK-N-BE(2)-C, SH-SY5Y and SK-N-AS cells on addition 
of Wnt3a/Rspo2. Green fluorescent staining shows β-catenin and cells were counterstained with DAPI (blue) for nuclei control D. Flow 
cytometry analysis of NB lines treated with Wnt3a/Rspo2 and labelled with Ki67 to measure proliferation. Note the shift and increased 
median fluorescence intensity (MFI) accompanying treatment. Note that x-axes are in log scale.
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unchanged and a slight increase of total ALK was observed 
in SH-SY5Y cells (Supplementary Figure 4). Thus LGR5 
does not exert its effect on MEK/ERK by influencing 
ALK activity. As the data above indicate different modes 
of signalling via LGR5, we tested whether the Wnt3a/
Rspo2 induced proliferation (Figure 2D) also necessitated 
increased MEK/ERK signalling. In contrast to the positive 
control for induction of proliferation, epidermal growth 
factor (EGF), Wnt3a/Rspo2 treatment did not lead to 
increased pMEK1/2 and pERK1/2 (Supplementary 
Figure 5).
Together these experiments demonstrate previously 
unknown pro-survival signalling activities mediated 
by LGR5 in addition to its well-established role in Wnt 
signalling amplification.
LGR5 is required for the G1 to S-phase cell cycle 
transition 
The dramatic effects of LGR5 levels on MEK/ERK 
signalling suggested to us that LGR5 may be involved in 
cell cycle regulation, as the MEK/ERK pathway is known 
to be a master regulator of the G1- to S-phase transition 
[33]. Depletion of LGR5 in SK-N-AS and SH-SY5Y cells 
led to a significant increase in the sub-G0/G1 population 
after a 72 hrs knockdown (Figure 6A). Evaluating 
cell cycle changes earlier (48 hrs) showed a significant 
increase in the G1/S-phase ratio, and that the cells 
accumulated in G1 phase, indicative of G1 arrest (Figure 
6B). Further, immunoblotting analysis of proteins involved 
in cell cycle progression showed a down regulation in 
the expression of phosphorylated Rb and cyclin E along 
with an increase in the expression of cell cycle inhibitor 
p27 (Figure 6C), thereby confirming G1 arrest of cells 
following LGR5 depletion. As these results indicated that 
LGR5 is required for G1 to S phase transition of cell cycle, 
we also investigated the expression of LGR5 during the 
cell cycle. SH-SY5Y cells were synchronised by serum 
starvation, fed with serum containing media after 48 hrs, 
and samples collected at 4 hr intervals. Immunoblotting 
demonstrated low LGR5 protein at 0 hrs when >85% of 
cells were in G1 phase, with increasing LGR5 as cells 
underwent a G1-S phase transition (16–20 hrs, Figure 6D). 
A strong inverse correlation between the percentage of 
Figure 3: LGR5 knockdown-induced cell death is independent of Wnt/β-catenin signalling pathway. A. SK-N-BE(2)-C, 
SK-N-AS and SH-SY5Y cells were transfected with siRNAs targeting LGR5 or β-catenin. LGR5 knockdown led to dramatic cell death 
in all three cell lines tested ( p < 0.05), but β-catenin depletion did not. B. Immunoblots confirming knockdowns and the absence of 
dephosphorylated (active) β-catenin. C: cytoplasmic, N: nuclear.
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cells distributed in G1 phase and expression of LGR5 is 
apparent (Supplementary Figure 6).
These data demonstrate for the first time that 
LGR5 has a role in regulating the cell cycle, and further 
emphasise the importance of LGR5 in regulating NB cell 
growth.
DISCUSSION
LGR5 has been shown to be highly expressed in 
a number of cancers, including colorectal cancer [34], 
breast cancer [20], cervical cancer [35] and glioblastoma 
[36], where it is associated with positive modulation of 
Wnt signalling in cancer stem cells. In this study, we 
demonstrate for the first time that LGR5 is also highly 
expressed in NB, where it modulates Wnt signalling 
associated with increased proliferation. Importantly, we 
also demonstrate novel regulatory properties of LGR5 
upstream of MEK/ERK and Akt pro-survival signalling, 
pathways that are frequently activated in primary 
neuroblastomas [10] (Figure 7).
Previous data has shown that NB cell lines do 
not exhibit any basal β-catenin-dependent TCF activity 
[24]. Consistent with this, we did not observe any 
reporter activity with neuroblastoma cell lines in the 
absence of Wnt3a and R-spondin ligands. Contrary 
to a previous report [33], however, we did not detect 
aberrant nuclear β-catenin in either MYCN-unamplified 
or MYCN-amplified NB lines, presumably because we 
used an antibody that specifically detects the active 
unphosphorylated form of β-catenin rather than total 
β-catenin [28]. Whilst this and another previous study 
have associated increased Wnt signalling with increased 
tumorigenicity based on induction of Wnt target genes 
in primary tumours and the development of highly 
tumorigenic sphere cultures [24, 25], our studies further 
directly demonstrate the proliferative capacity of Wnt3a/
Rspo2 on NB cells expressing LGR5. Wnt inducibility 
does not clearly segregate with any particular genotype, 
although we note that SH-SY5Y showed the smallest 
response to Wnt3a/Rspo2, probably due to ALK being 
its major driver. Our studies did not support the notion 
that aberrant Wnt signalling explains high c-MYC 
expression in MYCN-unamplified NB lines as previously 
suggested [24], as Wnt3a/Rspo2 treatment of SK-N-
AS and SH-SY5Y cells contrarily results in a slight 
decrease of c-MYC. A similar effect is also observed 
for MYCN in SK-N-BE(2)-C cells, and a significant 
transcriptional induction of MYC or MYCN genes after 
Wnt/Rspo2 treatment of SK-N-BE(2)-C cells was 
Figure 4: Depletion of LGR5 induces apoptosis in neuroblastoma cells. Knockdown of LGR5 with independent siRNAs 
induces apoptosis shown by cell-counts, increased cleaved PARP (cPARP), and rescue by the caspase 3 inhibitor QVD A. SK-N-AS cells 
and B. SH-SY5Y cells. Asterisks denote p < 0.05, and assays are representative of at least 3 biological replicates. Membrane asymmetry 
assessment of apoptosis in C. SK-N-AS cells and D. SH-SY5Y cells. EA, early apoptosis; LA, late apoptosis.
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not observed (Supplementary Figure 2). One possible 
explanation for this in SK-N-AS cells is the reduced 
MEK/ERK observed upon Wnt3a/Rspo2 stimulation 
(Supplementary Figure 5), as phosphorylation by this 
MAPK pathway has been shown to be involved in the 
stabilising phosphorylation of Serine 62 of c-MYC [37]. 
Context-dependent crosstalk between the Wnt and Ras-
Raf-MEK/ERK signalling has been shown previously, 
with Wnt signalling stabilising Ras in intestinal cancers 
[38], and the MAPK pathway repressing Wnt signalling 
in melanoma [39]. Whilst this is not the focus of our 
study and our data is limited to one time-point, it is 
possible that Wnt signalling in SK-N-AS cells dampens 
MEK/ERK signalling. Further transcriptomic and 
proteomic analyses of Wnt induction of NB in the 
future will help illuminate other growth regulatory and 
cross-talk mechanisms that may be involved in Wnt/
Rspo2 induced proliferation. In SH-SY5Y or SK-N-
BE(2)-C cells, decreased c-MYC and MYCN may 
rather be associated with lower Akt signalling, inhibition 
of PI3K/Akt having previously been shown to reduce 
MYCN levels [11].
Intriguingly, LGR5 knockdown resulted in 
pronounced cell death through apoptosis that was not 
apparent when β-catenin was knocked down. This 
demonstrated that LGR5 depletion mediated cell death 
is independent of Wnt/β-catenin signalling. Thus in 
addition to playing an important role in Wnt stimulated 
proliferation of NB cells, LGR5 is also required for 
the survival of NB cells. LGR5 knockdown in all three 
Figure 5: LGR5 regulates MEK/ERK and Akt signalling. Immunoblotting demonstrating A. decreases in p-ERK1/2 (T202/Y204) 
and p-MEK1/2 (S217/221), B. Elevated Bim-EL and C. altered Akt phosphorylation and Rictor levels accompanying LGR5 knockdown.
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of our tested cell lines led to a dramatic reduction in 
phosphorylated MEK/ERK which is a critical mediator 
of tumour cell survival [40] and repressor of apoptosis 
[30, 31]. MEK/ERK diminution was accompanied by an 
increase of the pro-apoptotic tumour suppressor BimEL. 
This capacity of LGR5 is reminiscent of brain-derived 
neurotrophic factor (BDNF)/tyrosine kinase receptor 
(TrkB) axis which has been shown to repress Bim via 
MEK/ERK phosphorylation [41] leading to increased 
resistance to chemotherapy in NB [42]. It will therefore be 
of great interest to examine LGR5 expression in a larger 
cohort of patients using immunohistochemistry to evaluate 
its prognostic significance, and assess its correlation with 
phosphorylated MEK/ERK/Akt in primary tumours. The 
ability of LGR5, a marker of stem cells in a variety of 
tissues [43], to govern MEK/ERK activity may also 
be integral to its role in stem cell maintenance, as high 
levels of MEK/ERK have been shown to be required 
for maintaining human embryonic stem cells in an 
undifferentiated state [44]. We did not detect upstream 
changes in total or phosphorylated (S338) c-Raf at time-
points where phosphorylated MEK/ERK was altered, 
suggesting that LGR5-mediated regulation of MEK/
ERK in NB cells is Raf-independent. Cells expressing 
ALK proteins have been shown to mediate MEK/ERK 
signalling independent of c-Raf, an effect that was 
attributable to an as yet unidentified kinase [45]. However, 
Raf phosphorylation patterns are complex and it remains 
possible that alternative post-translational modifications 
of Raf are involved [46]. Other kinases capable of Raf-
independent MEK/ERK activation such as COT/MAP3K8 
[47] may also be involved.
Figure 6: LGR5 is required for G1 to S phase transition. A. Increased sub-G0/G1 cells following LGR5 knockdown of SK-N-AS 
and SH-SY5Y cells demonstrated by flow cytometry. Asterisks denote p < 0.05. B. Cell cycle analysis of LGR5 knockdowns. After 48 hrs 
of transfection, G1 arrest of cells is apparent through comparison of G1-S phase ratios. Asterisks denote p < 0.05. C. Immunoblotting 
analysis of cell cycle regulatory proteins confirming G1 arrest accompanying LGR5 knockdown.D. Immunoblot demonstrating cell cycle 
dependent changes in LGR5 expression in SH-SY5Y cells. E. Quantification of LGR5 protein levels (relative to β-actin) plotted against 
percentage of cells in G1- or S-phase.
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Two of our three cell lines have NRAS mutations 
(SK-N-AS [12] and SH-SY5Y [48]), and, while the 
SK-N-BE(2)-C line does not (our unpublished data 
and reference 16), it has inactivating mutations of 
NF1, providing an alternate mechanism for activation 
of Ras signalling via neurofibromin down-regulation 
[49]. However while known to have mutant NRAS, SH-
SY5Y cells reportedly display no activated Ras-GTP 
[50]. Together this evidence suggests that the survival 
interference triggered by LGR5 depletion may involve 
not only Ras, but also other signal transduction pathways, 
and it is pertinent to note that GPCRs have been shown to 
signal directly to Src kinases [51] which also contribute 
to MEK/ERK activation [52]. Whilst a low level of Ras-
Raf-MEK/ERK pathways mutations have previously been 
observed in NB [5, 6], two very recent studies strongly 
associate Ras/MAPK pathway mutations with relapsing 
NB [13, 14]. Intriguingly, both these studies each include 
an individual relapsed tumour with missense mutations 
of LGR5, ie 2 mutations in a total of 39 relapsed tumours 
analysed (5%). Our functional analyses suggest that 
LGR5 might also be included in the mutational geneset 
of the Ras/MAPK pathway, and further strengthens the 
importance of Ras/MAPK to NB progression. Consistent 
with the notion of an LGR5-Ras-MEK/ERK axis, we 
have observed that treatment of our NB cell lines with 
Trametinib/GSK1120212 [53], a potent inhibitor of 
MEK1/2, leads to a rapid elimination of LGR5 (data not 
shown).
ERK1/2 signalling is known to play a crucial 
role in the G1-S phase progression of the cell cycle by 
negatively regulating the cell cycle inhibitor p27 [33], and 
consistent with this, reduction of MEK/ERK signalling 
in LGR5 depleted neuroblastoma cells led to a G1-phase 
cell cycle arrest. We also demonstrated that LGR5 is cell 
cycle regulated, being low in early G1 phase, peaking 
at G1-S phase transition, and then decreasing as cells 
progressed through S phase. These observations may 
have important implications for studies exploring LGR5 
regulation and those employing LGR5 as a marker of cell 
populations. Agents inducing G1-phase cell cycle arrest, 
for example, will appear to downregulate LGR5, although 
this effect may be indirect and attributable to the cell cycle 
distribution of the analysed cells. Similarly, cell-sorting 
of side-populations contingent on high LGR5 expression 
levels may be obfuscated by fluctuating expression levels 
during the cell cycle.
Our data also suggested that LGR5 may be 
upstream of Akt signalling. However, the pattern of Akt 
and PDK1 modifications suggests that rather than a direct 
effect (via PI3K/PDK1), or a kinase-dependent ERK/Akt 
crosstalk [54], the effects observed are due to the cell 
cycle arrest induced by LGR5 knockdown. The fact that 
only p-Akt (S473) decreased, whereas p-Akt (T308) did 
not, implicated mTORC2 involvement. This was further 
narrowed down to Rictor, which decreased dramatically, 
in contrast to mTOR which was unchanged. It was 
recently demonstrated that Rictor mRNA translation 
is exquisitely regulated at the G1-S transition, rising 
sharply in S-phase and phosphorylating p-Akt (S473) 
[55]. We therefore interpret the LGR5 depletion-induced 
effects on Akt as indirect and attributable to cell cycle 
arrest.
In summary, our data presented here highlights 
LGR5 as a candidate oncoprotein mediating key signalling 
pathways in NB and possibly other cancers, such as breast 
and cervical cancer, and glioblastoma. Antibodies such as 
BNC101 which target LGR5 may therefore a powerful 
therapeutic agents to be deployed in combination with 
kinase inhibitor therapies, particularly those targeting the 
MEK/ERK pathway such as Trametinib [53].
MATERIALS AND METHODS
Patient samples
All tissues were obtained as snap frozen samples 
from the Bristol Children’s Hospital. Details of clinical 
samples are given in Supplementary Table 2. For 
immunohistochemistry, neuroblastomas were from 
archival tissues collected at The Children’s Hospital at 
Westmead Histopathology Department (Sydney, Australia) 
since 1950, and assembled into a tissue microarray. All 
human tissues were acquired with appropriate local 
research ethics committee approval.
Figure 7: A model showing regulatory modalities 
for LGR5 in neuroblastoma. Pro-survival signalling 
of MEK/ERK activities which are R-Spondin independent 
are shown on the left, and may be inhibited by MEK/ERK 
inhibitors such as Trametinib. Proliferative Wnt signalling 
in the presence of Wnt/Rspos is shown on the right. FZD: 
Frizzled receptors; LRP: Low Density Lipoprotein Receptor-
Related Proteins, β-cat: β-catenin, TCF: T-cell factor/
lymphoid enhancer factor.
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Tissue culture
The NB cell lines used in this study are SK-N-BE(2)-C, 
IMR32, NGP (kindly provided by Pramila Ramani, Bristol 
Royal Infirmary, University of Bristol), GIMEN, SH-5Y 5Y 
(kindly provided by Carmel McConville, University of 
Birmingham), SK-N-BE(1)N, SHEP (kindly provided by 
Robert A Ross, Fordham University), SMS-KAN, SMS-
KANR, LAN5, LAN6 (purchased from the Children`s 
Oncology Group, USA), LAN1, KELLY, NBL-S 
(purchased from the Leibniz-Institut DSMZ - Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH) 
and SK-N-AS (Sigma). Cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) mixture F12-HAM 
(Sigma) supplemented with 10% fetal bovine serum 
(FBS) (PAA cell culture), 200 mM L-Glutamine (Sigma), 
100 mM penicillin, 0.1 mg/mL streptomycin (Sigma) and 
1% v/v non-essential amino acids (Life technologies) 
as adherent monolayers and maintained in a humidified 
incubator at 37ºC with 5% CO2.
siRNA knockdown in neuroblastoma cell lines
Knockdowns and cell treatments with QVD 
(quinolyl-valyl-O-methylaspartyl-(-2,6-difluorophenoxy)-
methyl ketone, Sigma) were carried out with 
Lipofectamine 2000 (Invitrogen) essentially as previously 
described [56]. Cells were transfected with 50 nM of small 
interfering RNA (siRNA) targeting LGR5. Individual 
siRNAs from the Dharmacon Smartpool of 4 siRNAs were 
used for LGR5 (DharmaconGE), as well as a fifth siRNA 
(5′-GCAUUUGUAGGCAACCCUU-3′). For CTNNB1, 
the siRNA was 5′-GGACCUAUACUUACGAAA-3′ 
(Sigma). For QVD treatment at 10 μM cells were 
incubated for 24 hrs before addition of the drug. Cells 
were then incubated for a further 48 hrs before harvesting, 
staining with Trypan Blue, and counting with an 
automated cell counter (Invitrogen) for the number of live 
and dead cells.
Protein expression analysis
Cells were lysed with cold cell lysis buffer (Cell 
Signalling Technology) with protease inhibitor (Roche) 
and phosphatase inhibitor (Roche). For preparation of 
cytoplasmic and nuclear protein fractions, cells were 
lysed as described previously, left on ice for 15 minutes 
and spun for 10 minutes at 13000rpm. The supernatant 
(cytoplasmic fraction) was transferred to a new tube and 
the remaining pellet was washed with PBS and lysed with 
1x nuclear lysis buffer (50 mM Tris-HCL (pH 8.1); 5 mM 
EDTA; 1% SDS) (nuclear fraction). The determination 
of cellular protein was done in accordance to a series 
of BSA standards using the Protein Assay kit (Bio-Rad) 
based on the Lowry assay [57]. Proteins were run in 
10–15% acrylamide gel (Severn Biotech) then transferred 
to a Immobilon-P PVDF membrane (Millipore) for 
probing with primary antibodies (listed in Supplementary 
Table 3).
Immunohistochemistry was performed with a Leica 
Microsystem Bond III automated machine using the Bond 
Polymer Refine Detection Kit (Ref DS9800) followed by 
Bond Dab Enhancer (AR9432). The slides were dewaxed 
with Bond Dewax Solution (AR9222). Heat mediated 
antigen retrieval was performed using Bond Epitope 
Retrieval Solution for 10 mins. Primary antibody dilution 
for anti-LGR5 (Proteintech 21833-1-AP) was1:400.
Wnt/β-catenin (TCF/LEF) reporter assays
TOPFLASH reporter assays were carried out 
as previously described with Super 8xTOPFLASH/
FOPFLASH (kindly supplied by R. Moon) [58]. 
Cells were seeded at a density of 5 x 104cells per 
well and incubated for 24 h before serum starvation 
and transfection with 8xTOPFLASH/FOPFLASH at 
100ng/ mL then incubated for a further 24 h. Cells 
were treated with recombinant human Wnt3a and/or 
R-spondins (Rspos) 1, 2 and 3 (R&D Systems) at 50ng/
mL and the activity was measured after 24 hrs using a 
luminometer (Modulus single tube multimode reader, 
Biosystems). For transfection with LGR5 or CTNNB1 
siRNA (50 nM), Dharmafect Duo (Thermo Scientific) 
was used. Twenty four hrs after transfection the cells were 
treated with Wnt3a and R-spondin 2 at 50 ng/mL each and 
the activity measured 24 hrs after treatment. Phosphate 
Buffered Saline (PBS)/0.02% (w/v) BSA was used as a 
control.
Confocal immunofluorescence
Cells were seeded onto Poly-L-lysine (Sigma) 
coated coverslips at a concentration of 3 × 105 cells/ 
well. Cells were serum starved for 24 hrs before 
treatment with Wnt3a and Rspo2 at 50 ng/mL and 
PBS/0.2% (w/v) BSA was used as a control. SK-N-
BE(2)-C, SH-SY5Y and SK-N-AS were fixed in 2% (v/v) 
paraformaldehyde (Sigma), permeabilised with 0.1% 
(v/v) Triton X-100 and stained with IgG1a monoclonal 
anti-β-catenin antibody (BD Biosciences). The threshold 
for β-catenin fluorescence was determined using isotype-
matched primary control antibody IgG1 k Isotype (BD 
Biosciences). Throughout image acquisition only whole 
nucleated cells were captured as determined by DAPI 
(4, 6 Diamino-2-Phenylindole, D9542, Sigma) staining. 
Confocal immunofluorescence was achieved using the 
resonant scanning head of a Leica TCS SP2 confocal laser 
microscope with a 63x oil immersion objective NA 1.32 
(HCX-PL-APO) assisted by Leica™ Confocal Software 
(LCS) version 2.61 (Leica Microsystems, Heidelberg, 
Germany).
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Ki67 proliferation assay
Cells were seeded at a density of 106 cells/well and 
serum starved for 24 hrs before treatment with epidermal 
growth factor (sigma) at 100 ng/mL, Wnt3a and Rspo2 at 
100 ng/mL. PBS/0.02% (w/v) BSA was used as a control. 
After 24 hrs cells were fixed with cold 70% ethanol and 
stained with PE Mouse Anti-Human Ki-67 according 
to the manufacturer’s protocol (BD Pharmingen). For 
measuring the threshold for Ki67 staining PE mouse 
IgG, Ƙ isotype control (BD Pharmingen) was used. 
Fluorescence of Ki67 stained cells was measured using a 
LSRFortessa X20 (BD Biosciences) using FACS DIVA8 
software (Becton-Dickinson Immunocytometry Systems, 
San Jose, CA, USA) and at least 20,000 events were 
collected. The results were analysed using FlowJo VX.0.7 
analysis software (Tree Star, Inc.).
Cell cycle analysis
Cells were seeded at a density of 106 cells/well and 
transfected with siRNA targeting LGR5. After 48–72 hrs 
of incubation cells were washed with PBS and fixed with 
cold 70% ethanol overnight before treatment with RNase 
A (Qiagen) at 100 μg/mL and stained with 50 μg/mL of 
Propidium Iodide (PI) (Sigma) in the dark for 30 minutes 
at 37ºC. DNA content of PI stained cells was measured 
as above.
For cell cycle synchronization analysis cells were 
serum deprived to promote cell cycle arrest. Medium 
containing 10% FBS was added to release cells from the 
arrest and samples were collected for protein expression 
analysis or fixed for cell cycle analysis every 4 hrs 
(0–32 hrs).
Violet ratiometric membrane asymmetry
Cells were seeded at a density of 106 cells/well 
and transfected with siRNA targeting LGR5. 72 hrs after 
transfection cells were washed with PBS and stained with 
F2N12S at 200nM and SYTOX® AADvanced™ dead cell 
stain (Life Technologies) at 1 nM and incubated for 5 mins 
in the dark at room temperature. Membrane asymmetry 
detection was measured in a BD LSR II flow cytometer 
(Becton-Dickinson Immunocytometry Systems, San 
Jose, CA, USA) using FACS DIVA8 software (Becton-
Dickinson Immunocytometry Systems, San Jose, CA, 
USA). At least 20,000 events were collected and the data 
was analysed using FlowJo VX.0. 7 analysis software 
(Tree Star, Inc.).
Wnt target gene transcript analysis
RNA purification and quantitative reverse-
transcriptase polymerase chain reaction (qRT-PCR) was 
carried out as before [56]. Serum-starved SK-N-BE(2)-C 
cells were stimulated with Wnt and R-spondin2 for 6 hrs. 
Primer sequences are given in Supplementary Table 4.
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